The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models

BACKGROUND/AIMS: The therapeutic options for metastatic neuroendocrine tumors (NETs) are limited. As PI3K signaling is often activated in NETs, we have assessed the effects of selective PI3Kp110α inhibition by the novel agent BYL719 on cell viability, colony formation, apoptosis, cell cycle, signali...

Descripción completa

Detalles Bibliográficos
Autores principales: Nölting, Svenja, Rentsch, Jakob, Freitag, Helma, Detjen, Katharina, Briest, Franziska, Möbs, Markus, Weissmann, Victoria, Siegmund, Britta, Auernhammer, Christoph J., Aristizabal Prada, Elke Tatjana, Lauseker, Michael, Grossman, Ashley, Exner, Samantha, Fischer, Christian, Grötzinger, Carsten, Schrader, Jörg, Grabowski, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553670/
https://www.ncbi.nlm.nih.gov/pubmed/28800359
http://dx.doi.org/10.1371/journal.pone.0182852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553670/
https://www.ncbi.nlm.nih.gov/pubmed/28800359
http://dx.doi.org/10.1371/journal.pone.0182852

Ejemplares similares